Janelle Goulard

Hard tech Investor @ Pangaea Ventures

📍 United States🔄 Updated October 2026💼 5 investments📅 9 years investing🗓 Last invested Jun 2026
VC🌍 United StatesInvested this year
5
Total investments
0
Early stage
3
Mid stage
1
Late stage
9y
Years active

Portfolio

5 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Observer
Jun 2026
Dioseve develops technologies to create fertilizable eggs from iPS cells / ES cells. By providing oocytes for couples who cannot give birth, we aim to establish unprecedented infertility treatment.
Board Observer
Jun 2024
We work to map the microbiome and illuminate interactions foundational to the health of humanity.
Board Member
Sep 2023
Carbon Project Development For a Sustainable Future. Biodel AG is dedicated to improving farm incomes, soil health, and sequestering carbon from the atmosphere.
late stageFarming
Board Member
Jun 2020
The microbiome is the new frontier gut health and changes to your microbiome signature is now being understood as a central conduit of health and disease. IBD, IBS, Crohns, colitis, type I diabetes, arthritis, metabolic syndrome, and several autoimmune disorders have all been associated with microbiome changes also known as dysbiosis. When you total the number of individuals affected by these diseases, over 80% Americans suffer from dysbiosis annually. With this much science there still arent real solutions for dysbiosis. And since dysbiosis is the result of changes to the 1000s different microbes of our gut it is nearly impossible to find the right remedy for your specific dysbiosis. Sun Genomics is empowering the consumer to educate themselves about their microbiome signature and make informed, as well as transparent, product selections to manage their dysbiosis. We are helping consumers realize the power of their microbiota through genomics, probiotics, microbiology, informatics, and software.
Investor
Oct 2017
Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders.
Experience · 8 entries
All (8)
Investments (5)
Board (4)
2026
Board Observer
Jun 2026
Dioseve develops technologies to create fertilizable eggs from iPS cells / ES cells. By providing oocytes for couples who cannot give birth, we aim to establish unprecedented infertility treatment.
2024
Board Observer
Jun 2024
We work to map the microbiome and illuminate interactions foundational to the health of humanity.
2023
Board Member
Sep 2023
Carbon Project Development For a Sustainable Future. Biodel AG is dedicated to improving farm incomes, soil health, and sequestering carbon from the atmosphere.
late stageFarming
2020
Board Member
Jun 2020
The microbiome is the new frontier gut health and changes to your microbiome signature is now being understood as a central conduit of health and disease. IBD, IBS, Crohns, colitis, type I diabetes, arthritis, metabolic syndrome, and several autoimmune disorders have all been associated with microbiome changes also known as dysbiosis. When you total the number of individuals affected by these diseases, over 80% Americans suffer from dysbiosis annually. With this much science there still arent real solutions for dysbiosis. And since dysbiosis is the result of changes to the 1000s different microbes of our gut it is nearly impossible to find the right remedy for your specific dysbiosis. Sun Genomics is empowering the consumer to educate themselves about their microbiome signature and make informed, as well as transparent, product selections to manage their dysbiosis. We are helping consumers realize the power of their microbiota through genomics, probiotics, microbiology, informatics, and software.
Partner
May 2020
For over 20 years, Pangaea Ventures has been at the forefront of hard tech innovation. We leverage our expertise to support groundbreaking companies that have the potential to reshape industries and solve for some of the planets biggest problems. We seek to generate meaningful returns for our investors by backing breakthrough innovations that deliver transformative solutions for planetary health.
Show all 8 entries ↓
Investment activity
2017–2026 · 5 investments
2017120201202312024120261
Recent (last 2 years)Earlier